NEW YORK – Alchemab and AstraZeneca on Wednesday announced a partnership to identify antibody-based prostate cancer therapies, as well as predictive and prognostic prostate cancer biomarkers.
Within the collaboration, Cambridge, UK-based Alchemab will use its drug discovery platform to sequence antibody repertoires in patients' samples and improve understanding of mechanisms that make some people resistant to disease through "naturally protective antibodies." Alchemab will also use its platform to home in on biomarkers of response to treatment and antibodies with therapeutic potential.
Alchemab will gain access to samples from prostate cancer patients enrolled in a trial for an immunotherapy AstraZeneca is developing. Then, in a joint proof-of-concept study, Alchemab will use its platform to identify antibody signatures among treatment responders.
"Our collaboration with AstraZeneca is a great opportunity to showcase Alchemab's novel technology," Jane Osbourn, Alchemab's CSO, said in a statement. "By working together to understand each patient's natural immunity, we anticipate that we will be able to build our understanding of prostate cancer disease biology and potentially deliver novel therapeutic options for patients with critical unmet need."
The collaboration with AstraZeneca comes after Alchemab recently closed a £60 million ($82 million) Series A financing round. The company plans to use the proceeds to advance its programs in cancer and neurodegeneration.